About Amsel Medical
Amsel Medical is a pre-commercialization stage medical device company founded in 2011 in Cambridge, MA. by world-renowned Vascular Surgeon Arnold Miller, MD. Amsel Medical boasts some of the industry’s most lauded professionals as part of the leadership team and Advisory Board. With three FDA Clearances and a CE Mark Clearance, the SCureClamp iDOT promises to meet unmet needs in the market and provide investors and physicians with a new standard of practice.
Making precise, site specific, highly targeted interventions possible
CEO
David Doster
30 years of medical device sales, marketing, product development, and M&A experience (AngioDynamics, Inc., VSP Medical, Innovative Aesthetic Technologies). Successfully managed multiple endovenous and peripheral vascular product lines and acquisitions. Past VP of American Venous Forum Foundation.
PRESIDENT & CMO
Arnold Miller, MD
Vascular Surgeon (Harvard Medical School, Mass General Hospital, MetroWest Medical Center) with more than 30 years experience treating venous reflux disease and peripheral vascular disease.
CTO
Raanan Miller, Ph.D
15 years of startup experience. Founder and CTO of Sionex Corporation, a venture-backed startup that commercialized products with General Dynamics, Thermo Fisher Scientific, Varian Instruments, and NASA. Winner of Frost and Sullivan 2010 Best New Spectrometry Award. Holds 60+ issued patents. Ph.D. Caltech, MBA MIT Sloan School of Management.
CCO
Robert Rossell
40 years of medical device experience. He was the former CEO of UVBioTek. Previous to this, Rob held leadership positions as the Vice President of Strategic Accounts for Surgical Specialties Corporation, and the U.S. General Manager for Nervomatrix. Rob was a Sr. Vice Presdident/General Manager and a founding member of the AngioDynamics management team, taking that business from start-up through public offering.
Sr. Vice President, Engineering
Jeff Willis
25+ years of experience in senior engineering, reseach and development and manufacturing. Jeff was a Director of Quality Assurance for Medline Industries. Previous to this he served at AngioDynamics as Director of Research and Development in addition to leadership roles within Manufacturing, Engineering and Quality Assurance.
Sr. Vice President, Strategic Development
James A. Heinz, MSL
39 years in healthcare. James founded the Center for Venous Disease and held key roles at Zimmer, Synthes, and Smith/Nephew in orthopedics and trauma. He also made significant contributions to the vascular space with VNUS Medical Technologies/ Medtronic and as a VENCLOSE C Suite Consultant/ Becton Dickinson. His expertise contributed to the successful exits in the chronic venous disease market at high valuation with VNUS and VENCLOSE. James holds a bachelor's degree in marketing and a master's degree in organizational leadership. Outside of healthcare, for over 15 years, James has been a United States Coast Guard Auxiliary Member supporting the operations of the United States Coast Guard under the supervision of the Department of Homeland Security.
In The News
AMSEL Medical Announces Appointment of Noam Karstaedt as a new Board Member
Amsel Medical today announced that Noam Karstaedt has been appointed to a new Board position effective February 29, 2024. With the addition of this appointment, Amsel Medical will have five full time Board members and three Board Observers.
David Doster, Amsel Medical CEO, commented that “We are pleased to welcome Noam to the Amsel Board at this time. Noam has been actively involved in supporting Amsel as a Board Observer over the last several years…..Read More
Amsel Medical Signs Know-How Agreement with Mayo Clinic to Advance Occlusion Technology
Amsel Medical, a medical device company pioneering novel vessel occlusion devices for minimally invasive percutaneous, laparoscopic, open surgical, or robotic placement, today announced a collaboration through a know-how agreement with Mayo Clinic to advance the development of this novel occlusion technology based on the Amsel platform.
“Saving Limbs, Saving Lives”
The collaboration brings together Amsel’s patented Interdigitation Occlusion Technology (iDOT™) with Mayo Clinic’s clinical know-how in vessel occlusion (veins, arteries, and tubular structures) during surgical and interventional procedures in vascular trauma, vascular access, and other interventional procedures…Read More
Amsel Medical's Selected for Presentation at 37th EAST Annual Scientific Assembly
Amsel Medical announced that an abstract detailing its groundbreaking innovation, SCureTO™, Saving Limbs and Lives: A Novel Percutaneous Vessel Occlusion Device to Combat Junctional Hemorrhage in Trauma, has been accepted for scientific presentation at the 37th EAST Annual Scientific Assembly. This presentation is scheduled on January 12, 2024, from 9:15 am to 9:30 am. This work underscores Amsel Medical's commitment to pushing the boundaries of medical innovation and improving patient outcomes in life-critical situations….Read More
SCureTO Trauma Solution Spotlighted at the Night Stalker Foundation Fund Raiser
Amsel Medical proudly supports the Night Stalker Foundation’s commemoration of the 30th Anniversary of Gothic Serpent, the Battle of Mogadishu, “Black Hawk Down.” This event is an opportunity to honor the service and sacrifice of the 160th Special Operations Aviation Regiment (Airborne). The event will be held at the One World Trade Observatory on Thursday, October 19th, 2023 from 6:00PM – 9:00PM…..Read More
Amsel Medical Highlighted at VEITH Symposium
Amsel Medical Corp. highlighted a presentation on the SCureClamp™ with Interdigitation Occlusion Technology (iDOT™) at the VEITH Symposium last week by Lowell S. Kabnick, MD. He described the need… Read More
Amsel Medical Announces $1.5 million AFWERX TACFI Grant Award
Tactical Funding Increase (TACFI) grants Amsel Medical significant further investment in support of improved urgent care for trauma. Amsel Medical Corporation recently… Read More
Amsel Medical Announces Appointment of Jeff Willis as Senior Director of Engineering
Amsel Medical Corp. today announced the appointment of Jeff Willis as Senior Director of Engineering to help drive the current product commercialization phase and implement the company’s strategy to address the demand for… Read More
Amsel Medical Announces Appointment of Robert M. Rossell as Chief Commercial Officer
Amsel Medical Corp. today announced the appointment of Robert M. Rossell as Chief Commercial Officer to drive the current commercial phase and implement the company’s strategy to address the demand for… Read more
Amsel Medical wins FDA nod for Endo Occluder
Amsel Medical said today that it won FDA 510(k) clearance for its Amsel Endo Occluder device intended for occluding blood vessels during endoscopic procedures… Read more
Dave Doster, CEO of Amsel Medical, presented at the esteemed LSI Emerging MedTech Summit on March 21, 2024, at Monarch Beach Resort
Regarded as “JPMorgan must-attend event for emerging MedTech companies”, the summit serves as a prime hub for leaders driving MedTech innovation. It's an unmatched forum for startups seeking funding and strategic partnerships to spark transformative healthcare solutions…. Read More
AMSEL Medical Announces Appointment of James A. Heinz, MSL as Senior Vice President Strategic Development
Amsel Medical Corporation announces the appointment of James A. Heinz as Senior Vice President Strategic Development to compliment our team as we commercialize the company and launch “game changing” technology that addresses the demand for minimally invasive, simple, and secure permanent vessel occlusion or temporary hemorrhage management…..Read More
Presenting Breakthrough Innovation at the Prestigious Joint Innovation Medical Symposium (JIMS)
Amsel Medical announced that they were selected to present at the Joint Innovation Medical Symposium (JIMS) at Pope Army Airfield/Fort Liberty, NC on November 9, 2023.
Amsel is one of only 20 companies invited to showcase their innovative technology and present their associated proposals for collaboration…..Read More
Amsel Medical Corp. selected for M2D2 IMPACT Cycle 4
Amsel Medical Corp. announced selection into the M2D2 IMPACT Cycle 4 accelerator program. IMPACT is a 12-week accelerator program that uses a unique one-on-one… Read More
Amsel Medical Announces Expanded Medical Advisor Group
Experienced team brings track record of quality product counsel for growth. Amsel Medical Corp. recently announced the expansion of its medical advisory team as the company advances the current product commercialization phase to address the demand for… Read More
The Next Evolution In Blood Vessel Occlusion
The good news for his patient was that she was young. A lower extremity bypass procedure - like any surgery - can be more difficult as we age. The bad news was that the best veins for the procedure - which involves grafting a vein from another part of the body to bypass her blocked arteries… Read More
Amsel Medical Announces Director of Clinical and Medical Affairs
Amsel Medical Corp. today announced the appointment of Lowell S. Kabnick as a consultant acting as Director of Clinical and Medical Affairs, as the company advances the current product commercialization phase to address the demand for… Read More
Amsel Medical Corporation Announces First In-Man Clinical Use of the Amsel Occluder Device at NYU Langone Medical Center.
Amsel Medical Corporation today announced First In-Man clinical use of the Amsel Occluder Device (AOD)1 at NYU Langone Medical Center, NY. The AOD2 was utilized during a variety of vascular surgical cases to ligate and occlude target vessels…Read More